The development of DAIDS Grade 3/4 ALT/AST elevations was further evaluated in patients categorized as having underlying liver disease (+LD; baseline transaminase elevations DAIDS Grade >1 [18] and/or hepatitis B/C virus [HBV/HCV] co-infection) or no underlying liver disease (-LD; baseline transaminase elevations Grade ≤ 1 and no HBV/HCV co-infection). The gene discussed is GPT; the disease is coinfection.